The DUO-O trial studied a new first-line treatment strategy for advanced ovarian cancer that combined chemotherapy, bevacizumab, durvalumab immunotherapy and later olaparib maintenance. It delayed cancer progression in the trial population without a tumour BRCA mutation, especially in cancers that were homologous recombination deficiency (HRD) positive. However, the results do not mean that every patient should receive this combination, and an overall-survival advantage has not yet been shown.
This page explains what the DUO-O results mean in patient language, how this approach differs from established PARP-inhibitor maintenance, and which test results and clinical questions matter before treatment decisions are made.
Evidence date: this page is based on the main DUO-O publication (Harter and colleagues, Annals of Oncology, published online December 2025). It reports progression-free survival results up to December 2022 and an early (interim) overall-survival analysis up to September 2023. Later results may change the picture. In Hindi, people often search for this as ovarian cancer me immunotherapy (ओवेरियन कैंसर में इम्यूनोथेरेपी) or for andashay ka cancer (अंडाशय का कैंसर) treatment.
On This Page
What Did the DUO-O Trial Show?
DUO-O was a phase 3 international clinical trial for people with newly diagnosed advanced epithelial ovarian, fallopian-tube or primary peritoneal cancer whose tumour did not carry a BRCA mutation. It tested whether adding the immunotherapy medicine durvalumab to chemotherapy and bevacizumab, then continuing durvalumab and bevacizumab with the PARP inhibitor olaparib, could keep the cancer controlled for longer.
The full combination improved progression-free survival compared with chemotherapy and bevacizumab followed by bevacizumab alone. Progression-free survival means the time during which a patient was alive without the cancer getting worse on scans or clinical assessment. It is an important treatment outcome, but it is not the same as overall survival, cure or quality of life.
The trial therefore provides encouraging evidence for a particular multi-drug strategy. It does not establish that the same plan is suitable for every patient with ovarian cancer. For the broader patient question, read whether immunotherapy works for ovarian cancer and who may benefit. Our treatment page on immunotherapy and eligibility explains how doctors decide who may be suitable; approvals can differ in India, and the team confirms what applies to you.
Which Treatments Were Combined in DUO-O?
The study treatment occurred in two connected phases:
- Initial or induction treatment: carboplatin and paclitaxel chemotherapy with bevacizumab and durvalumab.
- Maintenance treatment: durvalumab and bevacizumab with olaparib after the initial chemotherapy phase.
These medicines work in different ways:
- Carboplatin and paclitaxel are standard chemotherapy medicines used in advanced ovarian cancer.
- Bevacizumab blocks a signal involved in the formation of blood vessels that tumours use to grow.
- Durvalumab is an immune-checkpoint inhibitor targeting PD-L1. It aims to help immune cells recognise and attack cancer.
- Olaparib is a PARP inhibitor that interferes with cancer-cell DNA repair.
This was not a trial of one new tablet added after chemotherapy. It evaluated an intensive treatment sequence involving intravenous and oral medicines over an extended period.
Who Was Included in the Trial?
The trial randomly assigned 1,130 patients with newly diagnosed advanced ovarian cancer. The reported comparison focused on patients without a tumour BRCA mutation. Participants were well enough to receive combination systemic therapy and were treated within a controlled research protocol.
This matters because trial results cannot automatically be applied to:
- early-stage ovarian cancer;
- borderline ovarian tumours;
- people whose cancer has already returned after several treatments;
- patients with a tumour BRCA mutation, who may have other well-established PARP-maintenance options;
- patients unable to receive bevacizumab because of bleeding, bowel, wound-healing, blood-pressure or other risks; or
- patients with autoimmune disease or another reason immunotherapy may be unsafe.
A pathology review, tumour stage, surgical outcome, general health, kidney and liver function, BRCA result and HRD result all contribute to the decision.
How Much Difference Did the Full Combination Make?
At the prespecified primary analysis, the full durvalumab-and-olaparib strategy was compared with the control treatment.
- Among patients without a tumour BRCA mutation whose cancer was HRD positive, median progression-free survival was 37.3 months with the full combination and 23.0 months with control. The reported hazard ratio was 0.49.
- Across the complete trial population without a tumour BRCA mutation, median progression-free survival was 24.2 months with the full combination and 19.3 months with control. The reported hazard ratio was 0.63.
A hazard ratio describes the relative rate of progression or death during follow-up; it is not the percentage of patients cured. Median progression-free survival is the point at which half the study group had experienced progression or death and half had not. An individual patient’s outcome can be shorter or longer.
The larger apparent benefit in the HRD-positive group also shows why biomarker results are central to interpreting this treatment rather than an optional extra.
Did Durvalumab Immunotherapy Without Olaparib Help?
The trial included a separate durvalumab arm that did not add olaparib during maintenance. In the overall population without a tumour BRCA mutation, that arm did not show a statistically significant progression-free-survival improvement compared with control: median progression-free survival was 20.6 months versus 19.3 months, with a hazard ratio of 0.87.
This is an important limit. The study does not support the simple conclusion that “immunotherapy works for ovarian cancer.” The positive result came from the complete treatment strategy, and the trial was not designed to precisely measure how much of the benefit came from each component of the combination.
Why Do BRCA and HRD Test Results Matter?
BRCA testing and HRD testing answer related but different questions.
- A germline BRCA test looks for an inherited BRCA1 or BRCA2 variant in blood or saliva. It can affect treatment, personal cancer risk and relatives.
- A tumour BRCA test looks for a BRCA alteration in the cancer itself. Some tumour alterations are not inherited.
- An HRD test looks for a broader pattern of impaired DNA repair in the tumour. A cancer can be HRD positive even when no BRCA mutation is found.
DUO-O enrolled the randomized population after excluding tumour BRCA-mutated cancers. The strongest numerical progression-free-survival result was seen in the non-BRCA-mutated, HRD-positive group. Patients should therefore ask for the exact laboratory report rather than relying on the phrase “genetic test was normal.”
A negative BRCA result does not automatically mean the cancer is HRD negative, and neither result alone decides treatment without the full clinical picture.
Does the DUO-O Combination Help Patients Live Longer?
An overall-survival advantage has not yet been demonstrated. At the reported interim overall-survival analysis, the hazard ratio for the full combination versus control was 0.95 in the overall non-tumour-BRCA-mutated population. The result was immature and not statistically significant.
This does not prove that there is no survival benefit; longer follow-up is needed. It does mean that the page should not describe the regimen as proven to extend life or cure more patients.
Other uncertainties include:
- how the combination compares with current biomarker-directed maintenance choices in routine practice;
- which component or interaction produced the observed benefit;
- the long-term burden of using three maintenance medicines;
- quality-of-life effects for individual patients; and
- whether later treatments influence the final overall-survival result.
What Are the Side Effects and Practical Burdens?
The publication reported that safety was generally consistent with the known profiles of the individual medicines. That statement does not mean the combination is mild. Each medicine has clinically important risks, and using several medicines can increase monitoring and treatment burden.
- Chemotherapy can cause low blood counts, infection risk, fatigue, nausea, hair loss and nerve symptoms.
- Bevacizumab can cause high blood pressure, protein in the urine, bleeding, blood clots, poor wound healing and, rarely, bowel perforation or fistula.
- Durvalumab can cause immune-related inflammation affecting organs such as the lungs, bowel, liver, thyroid, adrenal or pituitary glands, skin and kidneys.
- Olaparib can cause nausea, fatigue, anaemia and other low blood counts. Rare serious blood or bone-marrow disorders are recognised risks.
Before considering a similar plan, the team reviews surgical healing, bowel involvement, blood pressure, urine protein, blood counts, organ function, autoimmune history, medicines and the patient’s priorities. New breathlessness, persistent diarrhoea, severe abdominal pain, fever, unusual bleeding or marked weakness during treatment needs prompt assessment.
Is This a Standard Treatment in India?
DUO-O is a clinical-trial result, and treatment availability can differ by country, hospital, regulatory approval, biomarker indication and funding. Durvalumab has approved uses in several cancers, and olaparib has established ovarian-cancer maintenance uses, but that does not automatically make the complete DUO-O regimen an approved or standard ovarian-cancer treatment in India.
Patients should ask the treating oncologist to verify the current regulatory status and local availability of the exact combination at the time of consultation. Off-label access, a clinical trial and a routinely approved treatment are different pathways. Cost and the need for repeated infusions, tablets, blood tests and scans also deserve discussion before a decision.
Established first-line choices remain individual. They can include surgery and platinum-based chemotherapy, bevacizumab for selected patients, and biomarker-directed maintenance with a PARP inhibitor. The DUO-O result should be considered within that broader pathway rather than used to replace it without specialist review.
What Should I Ask at an Ovarian-Cancer Consultation?
- What is the exact ovarian-cancer type and FIGO stage?
- Were both germline and tumour BRCA tests performed?
- Was HRD testing performed, and what does the full report say?
- Am I eligible for bevacizumab based on surgery, bowel involvement and blood pressure?
- Is immunotherapy appropriate with my autoimmune and medical history?
- Is the complete DUO-O combination approved and available for my situation?
- What is established standard treatment for my biomarker group?
- What benefit can reasonably be expected: tumour control, progression-free survival or overall survival?
- What side effects, monitoring, travel and costs would each option involve?
- Is there a suitable clinical trial?
- Would a gynaecological-oncology second opinion change the surgery or maintenance plan?
Frequently Asked Questions
What is DUO-O?
DUO-O is a phase 3 trial in newly diagnosed advanced ovarian cancer without a tumour BRCA mutation. It evaluated durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab and bevacizumab with or without olaparib.
Is durvalumab a PARP inhibitor?
No. Durvalumab is an immune-checkpoint inhibitor targeting PD-L1. Olaparib is the PARP inhibitor used in the full combination.
Is the DUO-O treatment only for BRCA-positive ovarian cancer?
No. The randomized population discussed in the published analysis did not have a tumour BRCA mutation. HRD status was still important, and the strongest reported progression-free-survival result was in the HRD-positive subgroup.
Does a BRCA-negative result mean I should receive this combination?
No. BRCA-negative status alone is not enough. HRD status, stage, pathology, surgical result, ability to receive bevacizumab and immunotherapy, approvals, availability and personal priorities must be considered.
Did DUO-O prove that immunotherapy alone improves ovarian-cancer outcomes?
No. The durvalumab arm without olaparib did not show a statistically significant progression-free-survival improvement in the overall non-tumour-BRCA-mutated population.
Does longer progression-free survival mean the cancer is cured?
No. It means the cancer remained controlled for longer on average before progression or death occurred. It does not establish cure or guarantee an individual result.
Has DUO-O shown that patients live longer?
Not yet. The reported interim overall-survival result did not show a statistically significant advantage, and longer follow-up is required.
Should I stop or change my maintenance treatment after reading this?
No. Do not start, stop or change cancer treatment based on an online article. Ask the treating team how this evidence relates to your pathology, biomarkers, previous treatment and current response.
Related Ovarian-Cancer Guidance
Read the broader guide to PARP-inhibitor maintenance after ovarian-cancer treatment, the complete ovarian-cancer treatment pathway, information about chemotherapy, or request a gynaecological-oncology second opinion.